Wide Ranks

ACHL

Achilles Therapeutics plc

1.07

Top Statistics
Market Cap 45 M Forward PE -1.23 Revenue Growth 0.00 %
Current Ratio 8.24 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.7080 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 95 M Total Cash Per Share 2.31 Total Debt 4 M
Total Debt To Equity 3.87 Current Ratio 8.24 Book Value Per Share 3.46
All Measures
Short Ratio 169.00 % Message Board Id finmb_408338329 Shares Short Prior Month 358114
Return On Equity -0.4422 City London Uuid cd1224e6-3b8c-3fc4-8e0c-3cb68aaed9cf
Previous Close 1.07 First Trade Date Epoch Utc 1 B Book Value 3.46
Beta 1.34 Total Debt 4 M Volume 98715
Price To Book 0.3088 Fifty Two Week Low 0.6300 Total Cash Per Share 2.31
Shares Short Previous Month Date 1 B Target Median Price 4.00 Max Age 86400
Recommendation Mean 2.00 Sand P52 Week Change 0.3133 Target Mean Price 4.00
Net Income To Common -63967000 Short Percent Of Float 0.0063 Implied Shares Outstanding 42 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 238450
Average Volume10days 238450 Total Cash 95 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0651 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.07 Target Low Price 2.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.01 Open 1.05
Free Cashflow -30137000 Dividend Yield 0.00 % Return On Assets -0.2682
Time Zone Short Name EST Trailing Eps -1.66 Day Low 1.04
Address1 245 Hammersmith Road Shares Outstanding 41 M Price Hint 4
Target High Price 6.00 Website https://www.achillestx.com 52 Week Change 0.2954
Average Volume 681148 Forward Eps -1.87 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 793.70 % Is_sp_500 False
Regular Market Day High 1.08 Profit Margins 0.00 % Debt To Equity 3.87
Fifty Two Week High 1.76 Day High 1.08 Shares Short 159245
Regular Market Open 1.05 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0039 Operating Cashflow -48000000
Currency USD Time Zone Full Name America/New_York Market Cap 45 M
Is_nasdaq_100 False Zip W6 8PW Quote Type EQUITY
Industry Biotechnology Long Name Achilles Therapeutics plc Regular Market Day Low 1.04
Held Percent Institutions 0.5930 Current Price 1.07 Enterprise To Ebitda 0.7080
Financial Currency USD Current Ratio 8.24 Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country United Kingdom Float Shares 20 M
Two Hundred Day Average 0.9402 Enterprise Value -46683944 Forward PE -1.23
Regular Market Volume 98715 Ebitda -65899000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors.

Its platform identifies mutations formed early in the development of cancer.

The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.

It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021.

Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.